What information does the instructions for Vemurafenib/Zobov contain?

Vemurafenib/Zelboraf(Vemurafenib) is a new anti-tumor drug whose trade names include Zelboraf and Zelboraf.

1. Indications:

The indications of vemurafenib mainly include two types of diseases:

1. Unresectable or metastatic melanoma: Vemurafenib is suitable for the treatment of patients with FDA-approved unresectable or metastatic melanoma who have been found to have BRAF V600E mutations. Melanoma is a type of skin cancer that has attracted attention from the medical community because of its tendency to metastasize and poor prognosis. Vemurafenib targets the mechanism of BRAF V600E mutation and can effectively inhibit the growth of tumor cells.

Restrictions on use: Vemurafenib is not indicated for the treatment of patients with wild-type BRAF melanomaThis means that the drug is only effective in patients with specific gene mutations.

2. Oldheim-Chester disease (ECD): Vemurafenib is also suitable for the treatment of patients with Erdheim-Chester disease who have BRAF V600 mutations. Erdheim-Chester disease is a rare disease of the vascular system, and the application of vemurafenib in this area provides patients with new treatment options.

2. Usage and dosage:

The dosage regimen of vemurafenib requires the guidance of a physician to ensure safety and efficacy.

1. Pre-medication examination: Before starting to use vemurafenib, doctors need to confirm whether there is BRAF V600E mutation in the patient's melanoma specimen. This test is a prerequisite for vemurafenib treatment.

2. Recommended dose: The recommended dose of vemurafenib is 960 mg orally every 12 hours, which usually corresponds to a dose of 4 tablets of 240 mg. The drug can be taken with or without food, and patients are advised to continue treatment as directed by their doctor until disease progression or unacceptable toxicity occurs.

3. Dosage adjustment: If adverse reactions occur after using vemurafenib, the patient should communicate with the doctor in time to adjust the dose, interrupt or stop the medication. At the same time, during treatment, patients should avoid concurrent use of strong CYP3A4 inducers. If this cannot be avoided, the dose of vemurafenib needs to be increased appropriately based on tolerance.

3. Adverse reactions:

Vemurafenib may cause a variety of adverse reactions during clinical application. The most common adverse reactions include joint pain, rash, hair loss, fatigue, photosensitivity reactions, nausea, itching, and benign skin tumors. Especially in patients receiving vemurafenib, skin-related adverse reactions are more prominent. The most common serious adverse reactions include cutaneous squamous cell carcinoma and rash. In addition, some other adverse reactions have occurred after vemurafenib was put on the market, such as the progression of chronic myelomonocytic leukemia, drug reactions, pancreatitis, etc.

4. Storage:

Strict regulations must be followed for the storage conditions of Vemurafenib. Medications should be stored at room temperature 20°C-25°C (68°F-77°F), with a temperature fluctuation between 15°C-30°C (59°F-86°F) allowed. Vemurafenib should be kept in the original container with a tight lid. When disposing of unused or expired drugs, attention should be paid to reducing the release of drugs to the environment, and drugs should not be disposed of through wastewater or household garbage to protect the ecological environment.

5. Mechanism of action:

Vemurafenib is a low molecular weight oralBRAF serine-threonine kinase inhibitor, which mainly targets mutant forms including BRAF V600E. Its mechanism of action is to reduce the proliferation of tumor cells by inhibiting abnormally activated BRAF protein. Certain mutations in the BRAF gene can lead to abnormal activation of its protein, causing continued cell proliferation in the absence of growth factors. It can produce anti-tumor effects in BRAF V600E mutated melanoma cells and animal models, thereby effectively combating melanoma and other related diseases.

Reference: https://www.drugs.com/mtm/vemurafenib.html